|
US7196078B2
(en)
*
|
2002-09-04 |
2007-03-27 |
Schering Corpoartion |
Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7196092B2
(en)
*
|
2002-09-04 |
2007-03-27 |
Schering Corporation |
N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7119200B2
(en)
*
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
EP1599482A4
(en)
*
|
2003-02-28 |
2008-10-01 |
Teijin Pharma Ltd |
PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
|
|
EP1608652A1
(en)
*
|
2003-03-31 |
2005-12-28 |
Vernalis (Cambridge) Limited |
Pyrazolopyrimidine compounds and their use in medicine
|
|
GB0321475D0
(en)
*
|
2003-09-12 |
2003-10-15 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2005035516A1
(ja)
*
|
2003-10-10 |
2005-04-21 |
Ono Pharmaceutical Co., Ltd. |
新規縮合複素環化合物およびその用途
|
|
JP2007536369A
(ja)
*
|
2004-05-06 |
2007-12-13 |
ファイザー・インク |
プロリン及びモルホリン誘導体の新規化合物
|
|
WO2005112936A1
(en)
*
|
2004-05-14 |
2005-12-01 |
The Regents Of The University Of Michigan |
Compositions and methods relating to protein kinase inhibitors
|
|
CN101005842A
(zh)
*
|
2004-05-28 |
2007-07-25 |
弗特克斯药品有限公司 |
蕈毒碱性受体调节剂
|
|
JP5208510B2
(ja)
*
|
2004-11-23 |
2013-06-12 |
アストラゼネカ・アクチエボラーグ |
呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
|
|
US7850960B2
(en)
*
|
2004-12-30 |
2010-12-14 |
University Of Washington |
Methods for regulation of stem cells
|
|
US7396929B2
(en)
*
|
2005-06-09 |
2008-07-08 |
Schering Corporation |
Synthesis of 3-amino-4-substituted pyrazole derivatives
|
|
EP1915377A1
(en)
*
|
2005-07-22 |
2008-04-30 |
Sunesis Pharmaceuticals, Inc. |
Pyrazolo pyrimidines useful as aurora kinase inhibitors
|
|
WO2007017678A1
(en)
*
|
2005-08-09 |
2007-02-15 |
Eirx Therapeutics Limited |
Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
|
|
CN101360499B
(zh)
*
|
2005-10-06 |
2015-10-07 |
默沙东公司 |
吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
AU2006336504C9
(en)
*
|
2005-12-28 |
2015-05-14 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
|
|
CA2643362A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Novartis Ag |
Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
|
|
KR20090019796A
(ko)
*
|
2006-05-22 |
2009-02-25 |
쉐링 코포레이션 |
ＣＤＫ 억제제로서의 피라졸로[1,5-ａ]피리미딘
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
US7786306B2
(en)
*
|
2006-08-18 |
2010-08-31 |
Schering Corporation |
Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same
|
|
WO2008021509A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Schering Corporation |
Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo [1,5-a] pyrimidine derivatives using same
|
|
CN101627041A
(zh)
*
|
2006-08-28 |
2010-01-13 |
先灵公司 |
合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体
|
|
MX2009002267A
(es)
*
|
2006-08-28 |
2009-03-20 |
Schering Corp |
Procedimiento e intermediarios para la sintesis de derivados e intermediarios de (3-alquil-5-piperidin-1-il-3,3a-dihidro-pirazolo [1,5-a]pirimidin-7-il)-amino.
|
|
EP2409700A1
(en)
|
2007-05-08 |
2012-01-25 |
Schering Corporation |
Methods of treatment using intravenous formulations comprising temozolomide
|
|
WO2008151304A1
(en)
*
|
2007-06-05 |
2008-12-11 |
Emory University |
Selective inhibitors for cyclin-dependent kinases
|
|
WO2009020140A1
(ja)
*
|
2007-08-06 |
2009-02-12 |
Dainippon Sumitomo Pharma Co., Ltd. |
アダマンチルウレア誘導体
|
|
WO2009023160A2
(en)
*
|
2007-08-11 |
2009-02-19 |
The Uab Research Foundation |
Novel inhibitors of bacterial sortase enzymes and methods of using the same
|
|
JP6151879B2
(ja)
|
2007-08-31 |
2017-06-21 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
体細胞を再プログラミングすることにおけるｗｎｔ経路の刺激
|
|
JP2010539173A
(ja)
*
|
2007-09-17 |
2010-12-16 |
シェーリング コーポレイション |
サイクリン依存キナーゼ阻害化合物を含む製剤およびこの製剤を用いて腫瘍を処置する方法
|
|
US20100286038A1
(en)
*
|
2007-09-21 |
2010-11-11 |
Valentyn Antochshuk |
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
|
|
WO2009055343A2
(en)
*
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
WO2009133522A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Actelion Pharmaceuticals Ltd |
Piperidine and pyrrolidine compounds
|
|
AU2009259867A1
(en)
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine JAK inhibitor compounds and methods
|
|
RU2560153C2
(ru)
|
2008-06-20 |
2015-08-20 |
Дженентек, Инк. |
Триазолпиридиновые соединения, ингибирующие jak, и способы
|
|
PT3106463T
(pt)
|
2008-10-22 |
2018-05-18 |
Array Biopharma Inc |
Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
|
|
WO2010068838A2
(en)
*
|
2008-12-11 |
2010-06-17 |
Emory University |
PROCESSES FOR PREPARING 5,7 DIAMINOPYRAZOLO[1,5-α] PYRIMIDINE COMPOUNDS
|
|
US8507673B2
(en)
*
|
2008-12-11 |
2013-08-13 |
Emory University |
Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds
|
|
WO2010118207A1
(en)
|
2009-04-09 |
2010-10-14 |
Schering Corporation |
Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
|
|
EP2421956A4
(en)
*
|
2009-04-24 |
2013-10-02 |
Whitehead Biomedical Inst |
COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
|
|
AR077468A1
(es)
*
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8993535B2
(en)
|
2009-09-04 |
2015-03-31 |
Merck Sharp & Dohme Corp. |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
WO2011119457A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Schering Corporation |
Process for synthesizing 6-bromo-3-(1-methyl-1h-pyrazol-4-yl)-5-(3(r)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
|
|
RU2735545C2
(ru)
|
2010-05-20 |
2020-11-03 |
Эррэй Биофарма Инк. |
Макроциклические соединения в качестве ингибиторов киназы trk
|
|
US8957077B2
(en)
|
2010-09-30 |
2015-02-17 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine PDE 10 inhibitors
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
EP3269802B1
(en)
|
2011-09-30 |
2019-10-23 |
Bluebird Bio, Inc. |
Compounds for improved viral transduction
|
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
EP2634190A1
(en)
|
2012-03-01 |
2013-09-04 |
Lead Discovery Center GmbH |
Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
|
|
EP2634189A1
(en)
*
|
2012-03-01 |
2013-09-04 |
Lead Discovery Center GmbH |
Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
|
|
WO2013148775A1
(en)
|
2012-03-30 |
2013-10-03 |
Merck Sharp & Dohme Corp. |
Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
EP2920181B1
(en)
|
2012-11-16 |
2019-01-09 |
University Health Network |
Pyrazolopyrimidine compounds
|
|
WO2014078802A1
(en)
|
2012-11-19 |
2014-05-22 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
|
US8871754B2
(en)
|
2012-11-19 |
2014-10-28 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
|
WO2014089379A1
(en)
|
2012-12-07 |
2014-06-12 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US9663519B2
(en)
|
2013-03-15 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
EP2970288A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP6586087B2
(ja)
|
2013-08-20 |
2019-10-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
|
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
AU2014337122B2
(en)
|
2013-10-18 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
|
WO2015085132A1
(en)
|
2013-12-06 |
2015-06-11 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
EP4512480A3
(en)
*
|
2013-12-20 |
2025-05-07 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
CN106029075A
(zh)
*
|
2014-01-09 |
2016-10-12 |
细胞内治疗公司 |
有机化合物
|
|
WO2015130585A1
(en)
|
2014-02-28 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Method for treating cancer
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
ES2873959T3
(es)
|
2014-05-28 |
2021-11-04 |
Piramal Entpr Ltd |
Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
|
|
HRP20200186T1
(hr)
|
2014-06-05 |
2020-05-29 |
Vertex Pharmaceuticals Inc. |
Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
|
|
JP6936007B2
(ja)
|
2014-06-17 |
2021-09-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
|
|
WO2015196072A2
(en)
|
2014-06-19 |
2015-12-23 |
Whitehead Institute For Biomedical Research |
Uses of kinase inhibitors for inducing and maintaining pluripotency
|
|
EP4183806A3
(en)
|
2014-11-12 |
2023-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
EP3218380B1
(en)
|
2014-11-16 |
2021-03-17 |
Array Biopharma, Inc. |
Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
|
|
EP3236959B1
(en)
|
2014-12-23 |
2025-09-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
AU2016243529B2
(en)
*
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
EP3355926B1
(en)
|
2015-09-30 |
2025-12-24 |
Vertex Pharmaceuticals Inc. |
Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
|
|
TN2019000271A1
(en)
|
2015-10-26 |
2021-01-07 |
Univ Colorado Regents |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
AU2016344040B2
(en)
|
2015-11-01 |
2020-12-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Wee 1 kinase inhibitors and methods of making and using the same
|
|
CN108463248B
(zh)
|
2015-11-12 |
2022-10-21 |
西雅图基因公司 |
聚糖相互作用化合物及使用方法
|
|
EP3377908B1
(en)
|
2015-11-18 |
2020-08-05 |
Genzyme Corporation |
Biomarker of polycystic kidney disease and uses thereof
|
|
ES2992295T3
(es)
|
2016-02-12 |
2024-12-11 |
Bluebird Bio Inc |
Composiciones potenciadoras de Vcn y métodos de uso de las mismas
|
|
US11326183B2
(en)
|
2016-02-12 |
2022-05-10 |
Bluebird Bio, Inc. |
VCN enhancer compositions and methods of using the same
|
|
IL304018A
(en)
|
2016-04-04 |
2023-08-01 |
Loxo Oncology Inc |
Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
IL297192A
(en)
|
2016-04-15 |
2022-12-01 |
Cancer Research Tech Ltd |
Heterocyclic compounds as ret kinase inhibitors
|
|
SMT202200348T1
(it)
|
2016-04-15 |
2022-11-18 |
Cancer Research Tech Ltd |
Composti eterociclici come inibitori della chinasi ret
|
|
ES2952056T3
(es)
|
2016-05-18 |
2023-10-26 |
Loxo Oncology Inc |
Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
CN108017641B
(zh)
*
|
2016-11-02 |
2021-01-05 |
深圳铂立健医药有限公司 |
吡唑并嘧啶化合物作为pi3k抑制剂及其应用
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
PT3579874T
(pt)
*
|
2017-02-10 |
2021-10-07 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
JP7216705B2
(ja)
|
2017-07-28 |
2023-02-02 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用方法
|
|
WO2019197549A1
(en)
|
2018-04-11 |
2019-10-17 |
Qurient Co., Ltd. |
Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
|
|
JP7590185B2
(ja)
|
2018-06-25 |
2024-11-26 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
|
|
JP7179161B2
(ja)
|
2018-09-10 |
2022-11-28 |
イーライ リリー アンド カンパニー |
乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
|
|
US11414431B2
(en)
|
2018-10-15 |
2022-08-16 |
Nimbus Lakshmi, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
|
|
MY210039A
(en)
|
2018-10-30 |
2025-08-22 |
Kronos Bio Inc |
Compounds, compositions, and methods for modulating cdk9 activity
|
|
AR117177A1
(es)
|
2018-12-10 |
2021-07-14 |
Lilly Co Eli |
DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
AU2019413694B2
(en)
|
2018-12-28 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
CN113874021B
(zh)
|
2019-03-26 |
2024-07-09 |
温缇克斯生物科学公司 |
Tyk2假激酶配体
|
|
AU2020378345A1
(en)
|
2019-11-08 |
2022-06-02 |
Ventyx Biosciences, Inc. |
TYK2 pseudokinase ligands
|
|
WO2021162944A1
(en)
|
2020-02-12 |
2021-08-19 |
Eli Lilly And Company |
Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
|
|
TWI810520B
(zh)
|
2020-02-12 |
2023-08-01 |
美商美國禮來大藥廠 |
7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
|
|
WO2021224633A1
(en)
|
2020-05-06 |
2021-11-11 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
US12371667B2
(en)
|
2021-05-13 |
2025-07-29 |
Washington University |
Enhanced methods for inducing and maintaining naive human pluripotent stem cells
|
|
CN116262752A
(zh)
*
|
2021-12-15 |
2023-06-16 |
上海壹迪生物技术有限公司 |
吡唑并嘧啶类化合物及其用途
|
|
CN119707984A
(zh)
*
|
2023-09-28 |
2025-03-28 |
中国科学院上海药物研究所 |
吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途
|